NEW YORK (GenomeWeb) – Cancer Genetics today said that its revenues in the second quarter rose nearly three-fold year over year, paced by a sharp spike in its biopharma services. 

The Rutherford, New Jersey-based cancer diagnostics firm reported total revenues of $4.2 million for the three months ended June 30, up from $1.5 million in the year-ago quarter. Its biopharma service business recorded $2.7 million in revenues, up from $400,000 a year ago, while its clinical service revenues rose 18 percent to $1.3 million from $1.1 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.